On Thursday, January 25, we are hosting our first internal workshop on the theme: “Triple-Negative Breast Cancer: A Dialogue Between Basic Science and Clinical Practice.”
Triple-negative breast cancers are estimated to account for 15% of breast cancers. This heterogeneous subgroup of breast tumors is characterized by the absence of the three most commonly found receptors in breast cancer tumor cells. Since conventional treatments target these receptors, triple-negative breast cancers are more challenging to treat.
In addressing this issue, Prof. Jean-Sébastien Frenel (oncologist at ICO) and Philippe Juin (director of CRCI2NA) have organized this workshop. Aimed at bringing together doctors and researchers working on this topic, the event promises enriching exchanges between translational research and clinical practice, exploring the latest developments in the treatment of triple-negative breast cancers.
We will also welcome Dr. Anne Patsouris (ICO), Vincent Guen (CRCI2NA), Pierre-François Cartron (CRCI2NA), Dr. Marie Robert (ICO), Nina Laurent (CRCI2NA), and Prof. Joseph Ciccolini (clinical pharmacologist at CHU de Marseille Timone).
Find the event program, organized by SIRIC ILIAD with institutional support from Gilead.
